الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

daiichi sankyo, inc. - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 20 mg - tribenzor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with tribenzor. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, det

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty mg) - tablet - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - olmesartan/ amlodipine hct - myl is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine besilate - film-coated tablet - 20 mg/5 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine besilate - film-coated tablet - 40 mg/10 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - olmesartan medoxomil; amlodipine besilate - film-coated tablet - 40 mg/5 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.9 mg - tablet, film coated - excipient ingredients: isopropyl alcohol; lactose monohydrate; pregelatinised maize starch; povidone; silicified microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - olmesartan/ amlodipine hct intas is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olmesartan medoxomil, quantity: 20 mg; hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.95 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; lactose monohydrate; silicified microcrystalline cellulose; povidone; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - olmesartan/ amlodipine hct intas indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 6.95 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; isopropyl alcohol; pregelatinised maize starch; povidone; silicified microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - olmesartan/ amlodipine hct intas is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - amlodipine besilate, quantity: 13.9 mg; olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; povidone; silicified microcrystalline cellulose; magnesium stearate; lactose monohydrate; isopropyl alcohol; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - olmakar hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination. this fixed dose combination is not indicated for initial therapy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; croscarmellose sodium; silicified microcrystalline cellulose; magnesium stearate; stearic acid; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - olmesartan and amlodipine tablets are indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.